P
Selected References
- PDF / 709,404 Bytes
- 67 Pages / 595.28 x 790.87 pts Page_size
- 18 Downloads / 198 Views
L.K. Golightly et al. (eds.), Renal Pharmacotherapy, DOI 10.1007/978-1-4614-5800-5_15, © Springer Science+Business Media New York 2013
511
Dosage Adjustment of Medications Eliminated by the Kidneys
Paliperidone - Selected References Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197:229–35. Berecz R, Llerena A, de la Rubia A, et al. Relationship between risperidone and 9-hydroxyrisperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry. 2002;35:231–4. Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol. 2009;49:1318–30. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38:393–414. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–317. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80–8. Gahr M, Kölle MA, Schönfeldt-Lecuona C, Lepping P, Freudenmann RW. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther. 2011;5:125–46. Gopal S, Gassmann-Mayer C, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26:377–87. Invega® extended release tablet [package insert]. Titusville: Janssen Pharmaceuticals Inc; 2011. Invega® Sustenna® injection [package insert]. Titusville: Janssen Division of Ortho-McNeil-Pharmaceuticals Inc; 2011. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993;21:1134–41. Mathot F, van Beijsterveldt L, Préat V, Brewster M, Ariën A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release. 2006;111:47–55. Maxwell RA, Sweet RA, Mulsant BH, et al. Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects. J Geriatr Psychiatry Neurol. 2002;15:77–81. Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol. 2010;66:797–803. Railton CJ, Kapur B, Koren G. Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle. Ther Drug Monit. 2005;27:558–61. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48:585–600. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical
Data Loading...
